Meropenem Kern Pharma (Meropenem Anhydrous)

Meropenem is indicated for severe infections caused by susceptible bacteria across several organ systems.

• Complicated intra‑abdominal infections: provides broad‑spectrum coverage to eradicate Gram‑negative, Gram‑positive and anaerobic pathogens.
• Complicated urinary tract infections: eliminates resistant Enterobacteriaceae and other uropathogens.
• Hospital‑acquired pneumonia and ventilator‑associated pneumonia: achieves bactericidal activity against common respiratory pathogens.
• Bacterial meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections.
• Sepsis and bloodstream infections: rapidly reduces bacterial load in systemic infections.

• Meropenem binds to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial cell death. The drug’s high affinity for a broad range of PBPs underlies its potent, bactericidal activity against many Gram‑negative, Gram‑positive and anaerobic organisms.

Adverse reactions may occur with meropenem therapy and are categorized by frequency.

Common Side Effects

• Nausea: mild to moderate gastrointestinal discomfort.
• Diarrhea: may be watery and self‑limiting.
• Rash: erythematous skin eruption.
• Headache: transient cranial discomfort.
• Elevated liver enzymes: transient increase in ALT/AST.
• Injection site phlebitis: local irritation at IV site.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Clostridioides difficile‑associated colitis: severe diarrhea due to bacterial overgrowth.
• Anaphylaxis: acute, potentially life‑threatening hypersensitivity.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Thrombocytopenia: reduced platelet count leading to bleeding risk.

Careful assessment and monitoring are required when using meropenem.

• Renal impairment: adjust dose based on creatinine clearance.
• Hypersensitivity: discontinue if allergic reaction occurs.
• Seizure risk: avoid in patients with a history of epilepsy or CNS disorders.
• Pediatric use: limit to approved indications and weight‑based dosing.
• Antimicrobial stewardship: restrict use to confirmed susceptible infections.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid)

• Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough.
• Other carbapenems: concurrent use may increase neurotoxicity.
• Aminoglycosides: combined nephrotoxic potential.
• Loop diuretics: heightened risk of renal dysfunction.

Moderate Interactions (Monitor Closely)

• Warfarin: monitor INR for possible anticoagulation changes.
• Oral contraceptives: consider alternative contraception methods.
• NSAIDs: observe renal function when co‑administered.
• Phenytoin: monitor serum levels for possible alteration.
• Other nephrotoxic agents: adjust dosing and monitor kidney function.